Join the Oncology Voice Network. Join for Free
What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms
Amplify Consulting Services field medical teams pharma leadership medical value proposition biotech industry insights

What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms


Share This Article


Summary

Today I have Craig Simms, CEO of Amplify Consulting Services and Former MSL Director of Astellas Pharma. Our topic for today is What’s Next: Co-creating the next reality for field medical teams following a global crisis. Really interesting topic, you’re going to enjoy it.

Key Points

  • What Craig is hearing from leaders in pharma, biotech, and medical device companies right now
  • Framework and powerful questions
  • Staying medically relevant, creating value, and value proposition
  • Advice to medical affair leaders in handling moral issues and getting people back to work (once the crisis is over)

Click for Source
Amplify Consulting Services, field medical teams, pharma leadership, medical value proposition, biotech industry insights

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Explore OVN